JP2011524898A5 - - Google Patents

Download PDF

Info

Publication number
JP2011524898A5
JP2011524898A5 JP2011514540A JP2011514540A JP2011524898A5 JP 2011524898 A5 JP2011524898 A5 JP 2011524898A5 JP 2011514540 A JP2011514540 A JP 2011514540A JP 2011514540 A JP2011514540 A JP 2011514540A JP 2011524898 A5 JP2011524898 A5 JP 2011524898A5
Authority
JP
Japan
Prior art keywords
disorder
pharmaceutically acceptable
formula
acceptable salt
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011514540A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524898A (ja
JP5468068B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2009/050763 external-priority patent/WO2009154563A1/en
Publication of JP2011524898A publication Critical patent/JP2011524898A/ja
Publication of JP2011524898A5 publication Critical patent/JP2011524898A5/ja
Application granted granted Critical
Publication of JP5468068B2 publication Critical patent/JP5468068B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011514540A 2008-06-20 2009-06-18 ジベンゾチアゼピン誘導体及びその使用 Expired - Fee Related JP5468068B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7441708P 2008-06-20 2008-06-20
US61/074,417 2008-06-20
PCT/SE2009/050763 WO2009154563A1 (en) 2008-06-20 2009-06-18 Dibenzothiazepine derivatives and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014011979A Division JP2014098006A (ja) 2008-06-20 2014-01-27 ジベンゾチアゼピン誘導体及びその使用

Publications (3)

Publication Number Publication Date
JP2011524898A JP2011524898A (ja) 2011-09-08
JP2011524898A5 true JP2011524898A5 (enExample) 2012-07-19
JP5468068B2 JP5468068B2 (ja) 2014-04-09

Family

ID=41431860

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011514540A Expired - Fee Related JP5468068B2 (ja) 2008-06-20 2009-06-18 ジベンゾチアゼピン誘導体及びその使用
JP2014011979A Pending JP2014098006A (ja) 2008-06-20 2014-01-27 ジベンゾチアゼピン誘導体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014011979A Pending JP2014098006A (ja) 2008-06-20 2014-01-27 ジベンゾチアゼピン誘導体及びその使用

Country Status (37)

Country Link
US (3) US20110160184A1 (enExample)
EP (1) EP2307389B1 (enExample)
JP (2) JP5468068B2 (enExample)
KR (1) KR20110019781A (enExample)
CN (1) CN102131791B (enExample)
AR (1) AR072200A1 (enExample)
AU (1) AU2009260905B2 (enExample)
BR (1) BRPI0914231A2 (enExample)
CA (1) CA2728675A1 (enExample)
CL (1) CL2010001471A1 (enExample)
CR (1) CR11860A (enExample)
CU (1) CU23884B1 (enExample)
CY (1) CY1113845T1 (enExample)
DK (1) DK2307389T3 (enExample)
DO (1) DOP2010000393A (enExample)
EA (1) EA201001889A1 (enExample)
EC (1) ECSP10010698A (enExample)
ES (1) ES2402084T3 (enExample)
HN (1) HN2010002683A (enExample)
HR (1) HRP20130234T1 (enExample)
IL (2) IL210081A (enExample)
ME (1) ME01516B (enExample)
MX (1) MX2010014203A (enExample)
MY (1) MY157518A (enExample)
NI (1) NI201000224A (enExample)
NZ (1) NZ590616A (enExample)
PE (1) PE20110029A1 (enExample)
PL (1) PL2307389T3 (enExample)
PT (1) PT2307389E (enExample)
RS (1) RS52703B (enExample)
SI (1) SI2307389T1 (enExample)
SV (1) SV2010003769A (enExample)
TW (1) TWI488854B (enExample)
UA (1) UA105903C2 (enExample)
UY (1) UY31919A (enExample)
WO (1) WO2009154563A1 (enExample)
ZA (1) ZA201100488B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488854B (zh) * 2008-06-20 2015-06-21 Astrazeneca Ab 二苯并噻氮呯衍生物及其用途
CN105981027A (zh) * 2013-08-12 2016-09-28 哥莱菲特软件公司 安全认证并切换至加密域
CN103524455A (zh) * 2013-10-30 2014-01-22 苏州敬业医药化工有限公司 一种制备2-氯-二苯并[b,f][1,4]硫氮杂卓-11-[10H]酮的方法
CN106134230A (zh) 2013-11-21 2016-11-16 哥莱菲特软件公司 用于移动信息设备上的远程内容和配置控制的管理域
CN104447615A (zh) * 2014-02-28 2015-03-25 广东东阳光药业有限公司 喹硫平中间体的制备方法
CN120981447A (zh) * 2023-03-08 2025-11-18 法兰克福大学 Slack激活化合物及其医学用途
EP4428132A1 (en) * 2023-03-08 2024-09-11 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Slack-activating compounds and their medical use

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL293201A (enExample)
NL294355A (enExample)
DE1620703B2 (de) * 1960-08-16 1976-11-25 Ausscheidung aus: 12 80 879 Dr. A. Wander AG, Bern 11-basisch substituierte dibenzo eckige klammer auf b,f eckige klammer zu-eckige klammer auf 1,4 eckige klammer zu-thiazepine
CH422793A (de) 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
DE1620713A1 (de) * 1962-05-25 1970-07-02 Wander Ag Dr A Verfahren zur Herstellung von 11-basisch substituierter Dibenzo[b,f][1,4]thiazepine
CH476753A (de) 1962-06-08 1969-08-15 Wander Ag Dr A Verfahren zur Herstellung von 11-basisch substituierter Dibenzo(b,f)(1,4)thiazepine
NL140242B (nl) 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
NL293210A (enExample) 1963-05-09
US3908010A (en) 1967-03-22 1975-09-23 Wander Ag Dr A Basically substituted heterocycles as anti-emetics
US3683034A (en) 1963-09-27 1972-08-08 Upjohn Co Process for the preparation of substituted hydroquinones
US3884920A (en) 1967-07-14 1975-05-20 Sandoz Ag 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines
US3412193A (en) 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
US3444169A (en) 1966-01-17 1969-05-13 American Cyanamid Co Process for 11 - aminodibenz(b,f)(1,4)oxazepines and analogous thiazepines
NL6715650A (enExample) 1966-12-16 1968-06-17
US3852446A (en) 1967-03-13 1974-12-03 Sandoz Ag Organic compounds in treatment of psychotic disturbances
US3758479A (en) 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CH569731A5 (enExample) * 1972-04-04 1975-11-28 Wander Ag Dr A
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
JPH0565257A (ja) 1991-07-05 1993-03-19 Hokuriku Seiyaku Co Ltd 多環式化合物及びその用途
US5661184A (en) 1994-08-12 1997-08-26 Eli Lilly And Company Psychiatric agents
CZ289512B6 (cs) 1994-08-24 2002-02-13 Astra Aktiebolag Spiro-azabicyklické sloučeniny pouľitelné při terapii
US5602121A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Alkyl-substituted compounds having dopamine receptor affinity
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
WO2001008680A1 (de) 1999-07-28 2001-02-08 Oswald Wiss Präparate mit sauerstoffsparender wirkung bei körperlicher leistung
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
AU2002249885A1 (en) 2000-11-17 2002-08-12 Adolor Corporation Delta agonist analgesics
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
ES2319876T3 (es) 2001-05-18 2009-05-14 Astrazeneca Ab Derivados de 4 (fenil-piperazinil-metil) benzamida y su uso para el tratamiento de la ansiedad o trastornos gastrointestinales.
SI1397366T1 (sl) 2001-06-01 2007-06-30 Astrazeneca Ab Nov ligand za nikotinske acetilholinske receptorje, koristen v terapiji
ES2330837T3 (es) 2001-07-09 2009-12-16 Combinatorx, Incorporated Combinaciones para el tratamiento de trastornos inflamatorios.
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
KR100996239B1 (ko) 2001-09-27 2010-11-23 바-일란 유니버시티 접합된 항-정신병 약물 및 그의 용도
US7417049B2 (en) 2002-04-18 2008-08-26 Astrazeneca Ab Furyl compounds
EP1499616B1 (en) 2002-04-18 2009-06-17 AstraZeneca AB Heterocyclic compounds
DE60333746D1 (de) 2002-04-18 2010-09-23 Astrazeneca Ab Thienylverbindungen
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
CN1681388A (zh) 2002-09-18 2005-10-12 Fmc有限公司 三环衍生物杀虫剂
EP1578198A1 (en) 2002-12-20 2005-09-28 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
MXPA05007784A (es) 2003-01-23 2005-09-30 Acadia Pharm Inc Empleo de la n-desmetilclozapina para tratar las enfermedades neuropsiquiatricas humanas.
EP1495008A1 (en) 2003-02-22 2005-01-12 Teva Pharmaceutical Industries Limited Synthesis of quetiapine and pharmaceutically acceptable salts thereof
DE10310196A1 (de) 2003-03-06 2004-09-23 Rina-Netzwerk Rna Technologien Gmbh Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
JP2006523707A (ja) 2003-04-15 2006-10-19 アストラゼネカ アクツィエボラーグ 治療化合物
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
PL195728B1 (pl) 2003-07-18 2007-10-31 Helm Ag Sposób wytwarzania 11-(1-piperazynylo)dibenzo[b,f][1,4]tiazepiny
RU2394030C2 (ru) * 2003-12-22 2010-07-10 Акадиа Фармасьютикалз Инк. АМИНОЗАМЕЩЕННЫЕ АНАЛОГИ ДИАРИЛ [a,d] ЦИКЛОГЕПТЕНА В КАЧЕСТВЕ МУСКАРИНОВЫХ АГОНИСТОВ И СПОСОБЫ ЛЕЧЕНИЯ ПСИХОНЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
PT1696931E (pt) 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
WO2006071730A1 (en) 2004-12-27 2006-07-06 Astrazeneca Ab Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders
WO2006073360A1 (en) * 2005-01-07 2006-07-13 Astrazeneca Ab NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
EP1865962A2 (en) * 2005-04-04 2007-12-19 Arcadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2008079847A1 (en) 2006-12-20 2008-07-03 Astrazeneca Ab (Se/Se) Compounds and uses thereof
WO2008100715A1 (en) 2007-02-09 2008-08-21 Astrazeneca Ab Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613
US7491871B2 (en) 2007-04-25 2009-02-17 Stine Seed Farm, Inc. Soybean cultivar S060299
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI488854B (zh) * 2008-06-20 2015-06-21 Astrazeneca Ab 二苯并噻氮呯衍生物及其用途

Similar Documents

Publication Publication Date Title
JP2011524898A5 (enExample)
JP2015501783A5 (enExample)
JP2007302689A5 (enExample)
JP2010077141A5 (enExample)
JP2013514980A5 (enExample)
JP2010529147A5 (enExample)
JP2009531376A5 (enExample)
JP2011518833A5 (enExample)
JP2010529118A5 (enExample)
JP2009242409A5 (enExample)
JP2009545527A5 (enExample)
JP2013512277A5 (enExample)
JP2013518107A5 (enExample)
JP2020502092A5 (enExample)
JP2008539268A5 (enExample)
CA2682494A1 (en) Hexahydro-1h-4,7-methanoisoindole-1,3-dione compounds for treating psychiatric disorders
JP2012504560A5 (enExample)
JP2011529502A5 (enExample)
JP2012519182A5 (enExample)
JP2007516193A5 (enExample)
JP2014526554A5 (enExample)
GB201020133D0 (en) Therapeutic use of compounds
JP2010521516A5 (enExample)
JP2008513510A5 (enExample)
JP2010527985A5 (enExample)